Targeted radiation blitz aimed at boosting stem cell transplant success for toughest blood cancers
NCT ID NCT03121014
Summary
This study is testing whether adding a precise, targeted form of radiation to the standard pre-transplant drug regimen can improve outcomes for adults with high-risk forms of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to better prepare the body to accept donor stem cells and reduce the chance of the cancer returning after the transplant. The main measure of success is how many patients survive for one year without their cancer relapsing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.